Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC
Contract research, development and manufacturing organisation Cohance Lifesciences, formerly Suven Pharmaceuticals, is strengthening its antibody-drug conjugate (ADC) strategy with fresh investments in two biotechnology companies. It is investing an additional $13 million in NJ Bio and making a controlling investment of $5 million in Aruka Bio, expanding its capabilities and presence in the growing ADC…